THE USAGE OF METOPROLOL TARTRATE IN ELDERLY AND OLD PATIENTS WITH CORONARY HEART DISEASE COMPLICATED BY CHRONIC HEART FAILURE

Aim of the study. To evaluate clinical efficacy and safety of metoprolol (Egiloc®) in treatment of Coronary Heart Disease (CHDO complicated by chronic heart failure (CHF) in elderly and old patients with normal and elevated blood pressure (BP), selection of optimal dose.Materials and methods. 43 pat...

Full description

Bibliographic Details
Main Authors: E. B. Nagaytseva, I. V. Vologdina, M. D. Malykina, I. V. Goncharova
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2003-06-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/1751
_version_ 1797857268266434560
author E. B. Nagaytseva
I. V. Vologdina
M. D. Malykina
I. V. Goncharova
author_facet E. B. Nagaytseva
I. V. Vologdina
M. D. Malykina
I. V. Goncharova
author_sort E. B. Nagaytseva
collection DOAJ
description Aim of the study. To evaluate clinical efficacy and safety of metoprolol (Egiloc®) in treatment of Coronary Heart Disease (CHDO complicated by chronic heart failure (CHF) in elderly and old patients with normal and elevated blood pressure (BP), selection of optimal dose.Materials and methods. 43 patients (mean age with 78.6 ± 3.8 years) with CHD complicated by CHF NYHA II functional class were treated by Egiloc® 25-100 mg daily for 17 days. Egiloc was added to baseline treatment with mononitrates and angiotensin converting enzyme (ACE) inhibitors. Clinical data, daily BP monitoring, echocardiography and 6-minutes walking test were evaluated.Results. Treatment with Egiloc® was accompanied by a reliable decrease in angina frequency and clinical features of CHF with no reliable changes in ejection fraction. There were no cases of hypotension in patients with normal BP levels taking 25-50 mg Egiloc® daily. Patients taking 25-50 mg Egiloc® daily demonstrated a reliable increase of physical stress tolerability, a reliable BP decrease and decreased incidence of BP elevations on BP daily monitoring. There were no cases of Egiloc® discontinuation die to poor tolerability.Conclusion. The results indicate that treatment with Egiloc® 25-100 mg daily is safe and effective in elderly and old coronary patients with CHF NYHA II functional class with normal and elevated BP. The drug's effect is dose-dependent.
first_indexed 2024-04-09T20:55:01Z
format Article
id doaj.art-181d4e2d9fe2458889c921082c329a63
institution Directory Open Access Journal
issn 1560-4071
2618-7620
language Russian
last_indexed 2024-04-09T20:55:01Z
publishDate 2003-06-01
publisher «FIRMA «SILICEA» LLC
record_format Article
series Российский кардиологический журнал
spelling doaj.art-181d4e2d9fe2458889c921082c329a632023-03-29T21:23:10Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202003-06-010345481515THE USAGE OF METOPROLOL TARTRATE IN ELDERLY AND OLD PATIENTS WITH CORONARY HEART DISEASE COMPLICATED BY CHRONIC HEART FAILUREE. B. Nagaytseva0I. V. Vologdina1M. D. Malykina2I. V. Goncharova3Госпиталь для ветеранов войн, Санкт-ПетербургГоспиталь для ветеранов войн, Санкт-ПетербургГоспиталь для ветеранов войн, Санкт-ПетербургГоспиталь для ветеранов войн, Санкт-ПетербургAim of the study. To evaluate clinical efficacy and safety of metoprolol (Egiloc®) in treatment of Coronary Heart Disease (CHDO complicated by chronic heart failure (CHF) in elderly and old patients with normal and elevated blood pressure (BP), selection of optimal dose.Materials and methods. 43 patients (mean age with 78.6 ± 3.8 years) with CHD complicated by CHF NYHA II functional class were treated by Egiloc® 25-100 mg daily for 17 days. Egiloc was added to baseline treatment with mononitrates and angiotensin converting enzyme (ACE) inhibitors. Clinical data, daily BP monitoring, echocardiography and 6-minutes walking test were evaluated.Results. Treatment with Egiloc® was accompanied by a reliable decrease in angina frequency and clinical features of CHF with no reliable changes in ejection fraction. There were no cases of hypotension in patients with normal BP levels taking 25-50 mg Egiloc® daily. Patients taking 25-50 mg Egiloc® daily demonstrated a reliable increase of physical stress tolerability, a reliable BP decrease and decreased incidence of BP elevations on BP daily monitoring. There were no cases of Egiloc® discontinuation die to poor tolerability.Conclusion. The results indicate that treatment with Egiloc® 25-100 mg daily is safe and effective in elderly and old coronary patients with CHF NYHA II functional class with normal and elevated BP. The drug's effect is dose-dependent.https://russjcardiol.elpub.ru/jour/article/view/1751ischemic heart diseasechronic heart failureelderly and old patientsэгилок®egiloc®
spellingShingle E. B. Nagaytseva
I. V. Vologdina
M. D. Malykina
I. V. Goncharova
THE USAGE OF METOPROLOL TARTRATE IN ELDERLY AND OLD PATIENTS WITH CORONARY HEART DISEASE COMPLICATED BY CHRONIC HEART FAILURE
Российский кардиологический журнал
ischemic heart disease
chronic heart failure
elderly and old patients
эгилок®
egiloc®
title THE USAGE OF METOPROLOL TARTRATE IN ELDERLY AND OLD PATIENTS WITH CORONARY HEART DISEASE COMPLICATED BY CHRONIC HEART FAILURE
title_full THE USAGE OF METOPROLOL TARTRATE IN ELDERLY AND OLD PATIENTS WITH CORONARY HEART DISEASE COMPLICATED BY CHRONIC HEART FAILURE
title_fullStr THE USAGE OF METOPROLOL TARTRATE IN ELDERLY AND OLD PATIENTS WITH CORONARY HEART DISEASE COMPLICATED BY CHRONIC HEART FAILURE
title_full_unstemmed THE USAGE OF METOPROLOL TARTRATE IN ELDERLY AND OLD PATIENTS WITH CORONARY HEART DISEASE COMPLICATED BY CHRONIC HEART FAILURE
title_short THE USAGE OF METOPROLOL TARTRATE IN ELDERLY AND OLD PATIENTS WITH CORONARY HEART DISEASE COMPLICATED BY CHRONIC HEART FAILURE
title_sort usage of metoprolol tartrate in elderly and old patients with coronary heart disease complicated by chronic heart failure
topic ischemic heart disease
chronic heart failure
elderly and old patients
эгилок®
egiloc®
url https://russjcardiol.elpub.ru/jour/article/view/1751
work_keys_str_mv AT ebnagaytseva theusageofmetoprololtartrateinelderlyandoldpatientswithcoronaryheartdiseasecomplicatedbychronicheartfailure
AT ivvologdina theusageofmetoprololtartrateinelderlyandoldpatientswithcoronaryheartdiseasecomplicatedbychronicheartfailure
AT mdmalykina theusageofmetoprololtartrateinelderlyandoldpatientswithcoronaryheartdiseasecomplicatedbychronicheartfailure
AT ivgoncharova theusageofmetoprololtartrateinelderlyandoldpatientswithcoronaryheartdiseasecomplicatedbychronicheartfailure
AT ebnagaytseva usageofmetoprololtartrateinelderlyandoldpatientswithcoronaryheartdiseasecomplicatedbychronicheartfailure
AT ivvologdina usageofmetoprololtartrateinelderlyandoldpatientswithcoronaryheartdiseasecomplicatedbychronicheartfailure
AT mdmalykina usageofmetoprololtartrateinelderlyandoldpatientswithcoronaryheartdiseasecomplicatedbychronicheartfailure
AT ivgoncharova usageofmetoprololtartrateinelderlyandoldpatientswithcoronaryheartdiseasecomplicatedbychronicheartfailure